Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a multicenter clinical research and focuses on the exploring of optimal diagnosis and treatment strategies of MDD based on anhedonia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University
• Treatments: Aripiprazole; Citalopram; Dexetimide

Criteria

Inclusion Criteria:

1. Major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5);

2. Age: 18-55 (including 18 and 55)

3. HAMD-17≥18

4. DARS ≤ 28

5. Do not receive repetitive Transcranial Magnetic Stimulation (rTMS) or modified electroconvulsive therapy (MECT) treatment in past six months.

6. Sign the informed consent form voluntarily and agree to participate in all visits, examinations and treatment as required by the trial protocol.

Exclusion Criteria:

1. Patients who are diagnosed with major somatic diseases;

2. Patients who meet DSM-5 diagnostic criteria for other mental disorders: Personality disorder, mental retardation; drug and/or alcohol dependence;

3. Patients with severe suicidal tendencies or suicidal behavior according to International Neuropsychiatric Interview Version 7.0-Suicide Module (MINI7.0-Suicide Module).

4. Pregnant or lactating women;

5. Patients with MRI contraindications;

6. Patients who are regarded as unsuitable by investigators for this clinical trial.